11/4/2023 0 Comments Keynote 355 sabcs![]() The toxicity profile was also really interesting. About 30% of the patients appeared to have had an anti TROP-2 ADC, which since we only have one other, I assumed to be sacituzumab. And many of those responses were quite durable with, very similar to what we’ve seen with sacituzumab actually. They saw a very nice response rate of 34%. And this antibody-drug conjugate is given every three weeks. There was a few patients treated at a higher dose, and the majority were treated at the final dose that is moving into phase three. But this study, which was really a trial looking at four different groups, and two per inter breast cancer were hormone receptor-positive and triple-negative disease, heavily pretreated, two more lines of therapy, and single-arm trial. And this is a really interesting novel ADC, a little bit different from some others, and similar to, again, TROP-2 antibody, but the toxicity profile interestingly is different from sacituzumab, and so it does bring up the question of, what the variations are and the construct of ADCs that ended up creating different profiles. This is a novel TROP-2 antibody linked to a toxin, which is deruxtecan, a derivative of deruxtecan, and it’s the same toxin that’s part of trastuzumab deruxtecan now approved for treating HER2-positive metastatic breast cancer. ![]() I specifically discussed 522 and 355, but not datopotamab, but I’ve also been very involved in discussing those results and participating in at least one of the two planned phase three trials with that agent. And those included the neoadjuvant study of pembrolizumab, KEYNOTE-522, the first-line metastatic study, KEYNOTE-355, and also the results of the phase one study of datopotamab as well in triple-negative breast cancer. Yes, so you had the privilege of discussing some of the triple-negative breast cancer abstracts while I was on route down from Toronto. And you had some questions you wanted to ask. So I think we’re gonna start discussing the first day. ![]() I discussed abstracts yesterday morning, and you discussed abstracts this morning for two of the four plenary sessions at this year San Antonio, a little bit different organization than the past due to the virtual format of the meeting, combined format. Great, and now both of us had actually the tremendous honor and pleasure of discussing abstracts. I’m from Princess Margaret Cancer Centre in Toronto, in the University of Toronto, where I’m a breast medical oncologist and clinician scientist. It’s great to be here in person with you, Hope, at the San Antonio Convention Center. Hello, and welcome to VJOncology’s breast cancer review from the San Antonio Breast Cancer Symposium 2021, where myself, Hope Rugo from the University of California, San Francisco’s Comprehensive Cancer Center, and my colleague David Cescon are here in person on site.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |